September 3, 2018
Life Science Leader
By Michael J. Flibbert; Megan Leinen Johns
Having a promising drug candidate in clinical trials can be an exciting time for a pharmaceutical company. It is also a time when it pays to think ahead on how best to position that drug candidate for patent coverage and how to withstand likely patent challenges. Most new drugs receive about 12 to 16 years of market exclusivity from the time of FDA approval. With patent protection serving an integral role in maintaining market exclusivity against generic competition, you need to understand how your actions may potentially affect patent coverage and enforcement. In this article Finnegan attorneys Mike Flibbert and Megan Leinen Johns discuss how to prepare a drug candidate for ANDA litigation.
Click here to read the full article.
Originally printed in Life Science Leader on September 3, 2018. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm's clients.
Hybrid Conference
Intellectual Property Law Institute 2026 – California
October 19-20, 2026
San Francisco
Hybrid Conference
Intellectual Property Law Institute 2026 – New York
September 28-29, 2026
New York
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.